8/16/2018
`NIH
`
`U.S. National Library of Medicine
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`National Center for Biotechnology Information
`
`O P E N
`CHEMISTRY
`D A T A B A S E
`
`Search Compounds
`
`
`
` Compound Summary for CID 92258
`
`Phenylacetylglutamine
`
` Cite this Record
`
`
`
`
`
`
`
`
`
`
`
`STRUCTURE
`
`VENDORS
`
`PHARMACOLOGY
`
`LITERATURE
`
`PATENTS
`
`BIOACTIVITIES
`
`PubChem CID:
`
`Chemical Names:
`
`Molecular Formula:
`Molecular Weight:
`InChI Key:
`Substance Registry:
`
`92258
`Phenylacetylglutamine; 28047-15-6; (S)-5-Amino-5-oxo-2-(2-phenylacetamido)pentanoic acid;
`Phenylacetyl-L-glutamine; Phenylacetyl L-Glutamine; PHENYLAC-GLN-OH More...
`
`C H N O
`13 16 2 4
`264.281 g/mol
`JFLIEFSWGNOPJJ-JTQLQIEISA-N
`
`FDA UNII
`
`Phenylacetylglutamine is a product formed from the conjugation of phenylacetate and glutamine. Technically, it is the amino
`acid acetylation product of phenylacetate (or phenylbutyrate after beta-oxidation). Phenylacetylglutamine is a normal
`constituent of human urine, but other mammals such as the dog, cat, rat, monkey, sheep, and horse do not excrete this
`compound. Phenylacetyl-CoA and L-glutamine react to form phenylacetylglutamine and coenzyme A. The enzyme
`(glutamine N-acetyl transferase) that catalyzes this reaction has been purified from human liver mitochondria and shown to
`be a polypeptide species distinct from glycine-N-acyltransferase. Phenylacetylglutamine is a major nitrogenous metabolite
`that accumulates in uremia (PMID: 2791363, 8972626). It has been shown that over 50% of urine phenylacetylglutamine may
`be derived from kidney conjugation of free plasma phenylacetic acid and/or from the kidney's preferential filtration of
`conjugated phenylacetic acid (PMID: 6420430).
`
` Metabolite Description from Human Metabolome Database (HMDB)
`
`PUBCHEM COMPOUND
`
`
`PHENYLACETYLGLUTAMINE
`
`
`
`Modify Date: 2018-08-15; Create Date: 2004-09-16
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`1/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 1 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
` Contents
`1 2D Structure
`2 3D Conformer
`3 Names and Identifiers
`4 Chemical and Physical Properties
`5 Related Records
`6 Chemical Vendors
`7 Pharmacology and Biochemistry
`8 Literature
`9 Patents
`10 Biomolecular Interactions and Pathways
`11 Biological Test Results
`12 Classification
`13 Information Sources
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`2/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 2 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`1 2D Structure
`
` Search
`
` Download
`
` Get Image
`
` Magnify
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`3/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 3 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`2 3D Conformer
`
` Search
`
` Download
`
` Get Image
`
`CLICK TO LOAD...
`
` Magnify
`
` Show Hydrogens
`
` Show Atoms
`
` Animate
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`4/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 4 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`3 Names and Identifiers
`
`3.1 Computed Descriptors
`
`3.1.1 IUPAC Name
`(2S)-5-amino-5-oxo-2-[(2-phenylacetyl)amino]pentanoic acid
`
`3.1.2 InChI
`InChI=1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)
`(H,18,19)/t10-/m0/s1
`
` from PubChem
`
` from PubChem
`
` from PubChem
`
` from PubChem
`
` from PubChem
`
` from PubChem
`
`3.1.3 InChI Key
`JFLIEFSWGNOPJJ-JTQLQIEISA-N
`
`3.1.4 Canonical SMILES
`C1=CC=C(C=C1)CC(=O)NC(CCC(=O)N)C(=O)O
`
`3.1.5 Isomeric SMILES
`C1=CC=C(C=C1)CC(=O)N[C@@H](CCC(=O)N)C(=O)O
`
`3.2 Molecular Formula
`C H N O
`13 16 2 4
`
`3.3 Other Identifiers
`
`3.3.1 CAS
`28047-15-6
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`5/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 5 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
` from ChemIDplus, EPA DSStox, Human Metabolome Database (HMDB)
`
`3.3.2 UNII
`92358I79RG
`
`3.3.3 Wikipedia
`
`Title
`Description
`
`3.4 Synonyms
`
`3.4.1 MeSH Entry Terms
`phenylacetylglutamine
`
`N(2)-phenylacetyl-L-glutamine
`chemical compound
`
` from FDA/SPL Indexing Data
`
` from Wikipedia
`
` from MeSH
`
`3.4.2 Depositor-Supplied Synonyms
`1. Phenylacetylglutamine
`2. 28047-15-6
`3. (S)-5-Amino-5-oxo-2-(2-phenylacetamido)pentanoic acid
`4. Phenylacetyl-L-glutamine
`5. Phenylacetyl L-Glutamine
`6. PHENYLAC-GLN-OH
`7. PA-L-Glutamine
`8. alpha-N-Phenylacetyl-L-glutamine
`9. L-N(sup 2)-(Phenylacetyl)glutamine
`10. NSC 203800
`
`11. L-Glutamine, N2-(phenylacetyl)-
`12. Glutamine, N2-(phenylacetyl)-, L-
`13. BRN 2593680
`14. UNII-92358I79RG
`15. JFLIEFSWGNOPJJ-JTQLQIEISA-N
`16. N(2)-(phenylacetyl)-L-glutamine
`17. N2-(2-Phenylacetyl)-L-glutamine
`18. 92358I79RG
`19. Glutamine, N(sup 2)-(phenylacetyl)-, L-
`20. (2S)-5-amino-5-oxo-2-[(2-phenylacetyl)amino]pentano
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`6/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 6 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`4 Chemical and Physical Properties
`
`4.1 Computed Properties
`
`Property Name
`Molecular Weight
`Hydrogen Bond Donor Count
`Hydrogen Bond Acceptor Count
`Rotatable Bond Count
`Complexity
`
`CACTVS Substructure Key Fingerprint
`
`Topological Polar Surface Area
`Monoisotopic Mass
`Exact Mass
`XLogP3-AA
`Compound Is Canonicalized
`Formal Charge
`Heavy Atom Count
`Defined Atom Stereocenter Count
`Undefined Atom Stereocenter Count
`Defined Bond Stereocenter Count
`Undefined Bond Stereocenter Count
`Isotope Atom Count
`Covalently-Bonded Unit Count
`
`4.2 Experimental Properties
`
`4.2.1 Physical Description
`Solid
`
`Property Value
`264.281 g/mol
`3
`4
`7
`338
`AAADceBzOAAAAAAAAAAAAAAAAAAAAAAAAAAwAAAA
`AAAAAAABAAAAHgAQCAAADCjBmAQwCILAAgCIAiHSGA
`ACAAAgAAAIiIGIAIgKIDKAlTGEYAAklgCYiAecn4COAAAAA
`AAAAAAAAAAAAAAAAAAAAAAAAA==
`110 A^2
`264.111 g/mol
`264.111 g/mol
`0
`true
`0
`19
`1
`0
`0
`0
`0
`1
`
` from PubChem
`
` from Human Metabolome Database (HMDB)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`7/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 7 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`4.3 Spectral Properties
`
`4.3.1 Mass Spectrometry
`
`4.3.1.1 General MS
`
`General MS: 1 of 5 (MS)
`MoNA ID
`MS Type
`MS Level
`Precursor Type
`precursor m/z
`Instrument
`Instrument Type
`Ionization Mode
`Collision Energy
`Splash
`
`Thumbnail
`
`EXPO_C4_5ppm_NEG_iTree
`Chromatography identified as LC-MS
`MS2
`[M-H]-
`263.15
`Thermo Finnigan LTQ
`Linear Ion Trap
`negative
`35%
`splash10-0002-0900000000-7a41ed1208e84f90c07c
`
`CLICK TO LOAD...
`
`Submitter
`
`Arpana Vaniya, University of California, Davis
`
` from MassBank of North America (MoNA)
`
`General MS: 2 of 5 (MS)
`MoNA ID
`MS Type
`MS Level
`Precursor Type
`precursor m/z
`Instrument
`Instrument Type
`
`EXPO_C4_5ppm_POS_iTree_02
`Chromatography identified as LC-MS
`MS2
`[M+Na]+
`287.12
`Thermo Finnigan LTQ
`Linear Ion Trap
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`8/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 8 of 26
`
`

`

`8/16/2018
`General MS: 2 of 5 (MS)
`Ionization Mode
`Collision Energy
`Splash
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`positive
`35%
`splash10-00di-0190000000-db5ec8a296288c1f176e
`
`CLICK TO LOAD...
`
`Thumbnail
`
`Submitter
`
`Arpana Vaniya, University of California, Davis
`
` from MassBank of North America (MoNA)
`
`General MS: 3 of 5 (MS)
`MoNA ID
`MS Type
`MS Level
`Precursor Type
`precursor m/z
`Instrument
`Instrument Type
`Ionization Mode
`Collision Energy
`Splash
`
`Thumbnail
`
`EXPO_C4_5ppm_POS_iTree_03
`Chromatography identified as LC-MS
`MS2
`[M+K]+
`303.23
`Thermo Finnigan LTQ
`Linear Ion Trap
`positive
`35%
`splash10-001l-0090000000-9ec4c0e4724d6b686f0f
`
`CLICK TO LOAD...
`
`Submitter
`
`Arpana Vaniya, University of California, Davis
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`9/26
`
` from MassBank of North America (MoNA)
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 9 of 26
`
`

`

`8/16/2018
`View All 5 General MS
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`4.3.1.2 GC-MS
`1. GC-MS Spectrum 10064 - GC-MS Ei Predicted by CFMID-EI, energy0
`2. GC-MS Spectrum 39005 - GC-MS Ei (1 TMS) Predicted by CFMID-EI, Ionization energy 70 eV fully TMS-derivatized
`(structure: C[Si](C)(C)OC(=O)[C@H](CCC(N)=O)NC(=O)CC1=CC=CC=C1)
` from Human Metabolome Database (HMDB)
`
`GC-MS: 1 of 1 (GC-MS Fields)
`NIST Number
`Library
`Total Peaks
`m/z Top Peak
`m/z 2nd Highest
`m/z 3rd Highest
`
`25421
`Main library
`35
`91
`118
`84
`
`CLICK TO LOAD...
`
`Thumbnail
`
`4.3.1.3 MS-MS
`
` from NIST
`
`1. MS-MS Spectrum 94506 - 10V Positive Predicted by CFM-ID
`2. MS-MS Spectrum 94507 - 20V Positive Predicted by CFM-ID
`3. MS-MS Spectrum 94508 - 40V Positive Predicted by CFM-ID
`4. MS-MS Spectrum 158538 - 10V Negative Predicted by CFM-ID
`5. MS-MS Spectrum 158539 - 20V Negative Predicted by CFM-ID
`6. MS-MS Spectrum 158540 - 40V Negative Predicted by CFM-ID
`7. MS-MS Spectrum 439962 - Linear Ion Trap negative instrument=Thermo Finnigan LTQ
`8. MS-MS Spectrum 450249 - Linear Ion Trap positive instrument=Thermo Finnigan LTQ
`9. MS-MS Spectrum 450250 - Linear Ion Trap positive instrument=Thermo Finnigan LTQ
` from Human Metabolome Database (HMDB)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`10/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 10 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`11/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 11 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`5 Related Records
`
`5.1 Related Compounds with Annotation
`
`CLICK TO LOAD...
`
` from PubChem
`
` from PubChem
`
`6 records
`3 records
`3 records
`17 records
`10 records
`14 records
`8 records
`
`12 records
`
`2648 records
`455 records
`
`5.2 Related Compounds
`
`Same Connectivity
`Same Stereo
`Same Isotope
`Same Parent, Connectivity
`Same Parent, Stereo
`Same Parent, Isotope
`Same Parent, Exact
`Mixtures, Components, and
`Neutralized Forms
`Similar Compounds
`Similar Conformers
`
`5.3 Substances
`
`5.3.1 Related Substances
`
`All
`Same
`Mixture
`
`109 records
`77 records
`32 records
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`12/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 12 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
` from PubChem
`
`5.3.2 Substances by Category
`
`CLICK TO LOAD...
`
`5.4 Entrez Crosslinks
`PubMed
`
`35 records
`
` from PubChem
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`13/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 13 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`6 Chemical Vendors
`
`CLICK TO LOAD...
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`14/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 14 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`7 Pharmacology and Biochemistry
`
`7.1 Human Metabolite Information
`
`7.1.1 Metabolite Description
`
`Description
`Phenylacetylglutamine is a product formed from the conjugation of phenylacetate and glutamine. Technically, it is the
`amino acid acetylation product of phenylacetate (or phenylbutyrate after beta-oxidation). Phenylacetylglutamine is a
`normal constituent of human urine, but other mammals such as the dog, cat, rat, monkey, sheep, and horse do not
`excrete this compound. Phenylacetyl-CoA and L-glutamine react to form phenylacetylglutamine and coenzyme A. The
`enzyme (glutamine N-acetyl transferase) that catalyzes this reaction has been purified from human liver mitochondria and
`shown to be a polypeptide species distinct from glycine-N-acyltransferase. Phenylacetylglutamine is a major nitrogenous
`metabolite that accumulates in uremia (PMID: 2791363, 8972626). It has been shown that over 50% of urine
`phenylacetylglutamine may be derived from kidney conjugation of free plasma phenylacetic acid and/or from the kidney's
`preferential filtration of conjugated phenylacetic acid (PMID: 6420430).
`
` from Human Metabolome Database (HMDB)
`
`7.1.2 Cellular Locations
`CytoplasmExtracellular
`
`7.1.3 Metabolite Pathways
`Phenylacetate Metabolism
`
` from Human Metabolome Database (HMDB)
`
` from Human Metabolome Database (HMDB)
`
`7.1.4 Associated Disorders and Diseases
`Colorectal cancer
`Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-
`methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995
`May;176(1):61-8.[PMID:7482520]
`Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W:
`Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi:
`10.1021/pr201001a. Epub 2011 Dec 28.[PMID:22148915]
`Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human
`colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.[PMID:19006102]
`Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences
`between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi:
`10.1371/journal.pone.0070803. Print 2013.[PMID:23940645]
`Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer.
`Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.[PMID:24424155]
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`15/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 15 of 26
`
`

`

`8/16/2018
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-
`Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB:
`Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients:
`implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.
`[PMID:20156336]
`Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human
`colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.
`[PMID:19678709]
`Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker
`discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.[PMID:25105552]
`Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M:
`Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012
`May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.[PMID:21773981]
`Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay
`performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131.
`Epub 2014 Jul 18.[PMID:25037050]
`Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and
`Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection
`2016.[PMID:27015276]
`Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of
`earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi:
`10.18632/oncotarget.8762.[PMID:27107423]
`Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from
`human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y.
`eCollection 2016.[PMID:27275383]
`Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and
`healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.
`[PMID:28587349]
`Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical
`consideration. Trends in Food Science & Technology. Vol. 57, Part B, Nov. 2016, p.244-255:
`http://www.sciencedirect.com/science/article/pii/S0924224416301984
`
` from Human Metabolome Database (HMDB)
`
`Eosinophilic esophagitis
`Mordechai, Hien, and David S. Wishart
`
` from Human Metabolome Database (HMDB)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`16/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 16 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`8 Literature
`
`8.1 Depositor Provided PubMed Citations
`
`CLICK TO LOAD...
`
`8.2 NLM Curated PubMed Citations
`
`CLICK TO LOAD...
`
` from PubChem
`
` from PubChem
`
`8.3 Synthesis References
`Suyama, Tadashi; Toyoda, Takeshi; Kanao, Seizo. N-Phenylacetyl amino acids and their homologs. I. N-Acylamino acids.
`Yakugaku Zasshi (1965), 85(4), 279-83. CODEN: YKKZAJ ISSN:0031-6903. CAN 63:39385 AN 1965:439385
` from Human Metabolome Database (HMDB)
`
`8.4 Metabolite References
`
`1 to 3 of 3
`Reference
`PMID
`6420430 Karoum F, Chuang LW, Mosnaim AD, Staub RA, Wyatt RJ: Plasma and cerebrospinal fluid concentration of
`phenylacetic acid in humans and monkeys. J Chromatogr Sci. 1983 Dec;21(12):546-50.
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`17/26
`
` Download
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 17 of 26
`
`

`

`8/16/2018
`PMID
`
`2791363
`
`8972626
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`Reference
`Zimmerman L, Egestad B, Jornvall H, Bergstrom J: Identification and determination of
`phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients. Clin Nephrol. 1989
`Sep;32(3):124-8.
`Shockcor JP, Unger SE, Wilson ID, Foxall PJ, Nicholson JK, Lindon JC: Combined HPLC, NMR spectroscopy,
`and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and
`endogenous metabolites in human urine. Anal Chem. 1996 Dec 15;68(24):4431-5.
`
` from Human Metabolome Database (HMDB)
`
`8.5 Springer Nature References
`
`CLICK TO LOAD...
`
`8.6 Chemical Co-Occurrences in Literature
`
`CLICK TO LOAD...
`
` from Springer Nature
`
`View More Chemical-Chemical Co-Occurrences and Evidence for Phenylacetylglutamine
`
` from PubChem
`
`8.7 Chemical-Disease Co-Occurrences in Literature
`
`CLICK TO LOAD...
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`18/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 18 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`View More Chemical-Disease Co-Occurrences and Evidence for Phenylacetylglutamine
`
` from PubChem
`
`8.8 Chemical-Gene Co-Occurrences in Literature
`
`CLICK TO LOAD...
`
`View More Chemical-Gene Co-Occurrences and Evidence for Phenylacetylglutamine
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`19/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 19 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`9 Patents
`
`9.1 Depositor-Supplied Patent Identifiers
`
`CLICK TO LOAD...
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`20/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 20 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`10 Biomolecular Interactions and Pathways
`
`10.1 Biosystems and Pathways
`
`CLICK TO LOAD...
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`21/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 21 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`11 Biological Test Results
`
`11.1 BioAssay Results
`
`CLICK TO LOAD...
`
` from PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`22/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 22 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`12 Classification
`
`12.1 Ontologies
`
`12.1.1 MeSH Tree
`
`CLICK TO LOAD...
`
`12.1.2 ChEBI Ontology
`
`CLICK TO LOAD...
`
`12.1.3 WIPO IPC
`
`CLICK TO LOAD...
`
` from MeSH
`
` from ChEBI
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`23/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 23 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
` from WIPO
`
`12.1.4 ChemIDplus
`
`CLICK TO LOAD...
`
` from ChemIDplus
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`24/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 24 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`
`13 Information Sources
`1. ChemIDplus /source/ChemIDplus
`Phenylacetylglutamine
`https://chem.nlm.nih.gov/chemidplus/sid/0028047156 https://chem.nlm.nih.gov/chemidplus/sid/0028047156
`ChemIDplus Chemical Information Classification
`https://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp https://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp
`2. EPA DSStox /source/EPA DSStox
`Phenylacetylglutamine
`https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID90182324 https://comptox.epa.gov/dashboard/dsstoxdb/results?
`search=DTXSID90182324
`3. Human Metabolome Database (HMDB) /source/Human Metabolome Database (HMDB)
`Phenylacetylglutamine
`http://www.hmdb.ca/metabolites/HMDB0006344 http://www.hmdb.ca/metabolites/HMDB0006344
`4. FDA/SPL Indexing Data /source/FDA/SPL Indexing Data
`92358I79RG
`https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/
`https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/
`5. MassBank of North America (MoNA) /source/MassBank of North America (MoNA)
`Unknown
`http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=JFLIEFSWGNOPJJ-JTQLQIEISA-N
`http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=JFLIEFSWGNOPJJ-JTQLQIEISA-N
`6. NIST /source/NIST
`L-Glutamine, N2-(phenylacetyl)-
`http://www.nist.gov/srd/nist1a.cfm http://www.nist.gov/srd/nist1a.cfm
`7. Springer Nature /source/Springer Nature
`Literature references related to scientific contents from Springer Nature journals and books. Read more ... https://link.springer.com/
`8. Wikipedia /source/Wikipedia
`N(2)-phenylacetyl-L-glutamine
`https://en.wikipedia.org/wiki/Phenylacetylglutamine https://en.wikipedia.org/wiki/Phenylacetylglutamine
`9. PubChem
`Data deposited in or computed by PubChem
`https://pubchem.ncbi.nlm.nih.gov https://pubchem.ncbi.nlm.nih.gov
`10. MeSH /source/MeSH
`phenylacetylglutamine
`https://www.ncbi.nlm.nih.gov/mesh/67003089 https://www.ncbi.nlm.nih.gov/mesh/67003089
`MeSH Tree
`http://www.nlm.nih.gov/mesh/meshhome.html http://www.nlm.nih.gov/mesh/meshhome.html
`11. ChEBI /source/ChEBI
`ChEBI Ontology
`http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
`http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
`12. WIPO /source/WIPO
`International Patent Classification
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`25/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 25 of 26
`
`

`

`8/16/2018
`
`Phenylacetylglutamine | C13H16N2O4 - PubChem
`http://www.wipo.int/classifications/ipc/ http://www.wipo.int/classifications/ipc/
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Phenylacetylglutamine
`
`26/26
`
`Par Pharmaceutical, Inc. Ex. 1029
`Par v. Horizon, IPR of Patent No. 9,561,197
`Page 26 of 26
`
`